Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Br J Haematol. 2011 Apr;153(1):105-10. doi: 10.1111/j.1365-2141.2011.08580.x. Epub 2011 Feb 20.
Sickle cell disease (SCD) is characterized by vasculopathy, which has been causally linked to intravascular haemolysis and high levels of free plasma haemoglobin. Soluble CD163 (sCD163) is implicated in the clearance of free plasma haemoglobin and high plasma concentrations have been linked to arterial disease. We therefore investigated the value of sCD163 as a biomarker in children with SCD, and also measured haptoglobin levels in this population. We measured sCD163 in 25 control children with no haemoglobinopathy, 41 with sickle cell anaemia (HbSS) in the steady state, 27 with HbSS taking hydroxycarbamide, and 7 with HbSC disease. There was no significant difference between sCD163 levels in steady-state HbSS (1·78 mg/l) and controls (1·81 mg/l) (P = 0·86). However, sCD163 levels were significantly lower in those HbSS children taking hydroxycarbamide (1·35 mg/l) compared to both steady state HbSS (P = 0·004) and controls (P = 0·036). In children on hydroxycarbamide, sCD163 correlated negatively and highly significantly with percentage HbF (R = -0·76, P < 0·001), and this relationship was absent in those not taking hydroxycarbamide (R = 0·07, P = 0·65). sCD163 is a potentially useful biomarker in children with SCD, and may have a role in monitoring responses to hydroxycarbamide.
镰状细胞病（SCD）的特征是血管病变，这与血管内溶血和游离血浆血红蛋白水平升高有关。可溶性 CD163（sCD163）与游离血浆血红蛋白的清除有关，高血浆浓度与动脉疾病有关。因此，我们研究了 sCD163 作为 SCD 儿童生物标志物的价值，并在该人群中测量了触珠蛋白水平。我们测量了 25 名无血红蛋白病的对照儿童、41 名镰状细胞贫血（HbSS）稳定期儿童、27 名服用羟基脲的 HbSS 儿童和 7 名 HbSC 疾病儿童的 sCD163 水平。稳定期 HbSS（1.78 mg/l）和对照组（1.81 mg/l）之间的 sCD163 水平没有显著差异（P = 0.86）。然而，服用羟基脲的 HbSS 儿童的 sCD163 水平明显低于稳定期 HbSS（P = 0.004）和对照组（P = 0.036）。在服用羟基脲的儿童中，sCD163 与 HbF 百分比呈负相关且高度显著（R = -0.76，P ＜0.001），而在未服用羟基脲的儿童中则不存在这种关系（R = 0.07，P = 0.65）。sCD163 是 SCD 儿童的一种潜在有用的生物标志物，可能在监测羟基脲反应方面发挥作用。
